Price T Rowe Associates Inc Neurocrine Biosciences Inc Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,086,457 shares of NBIX stock, worth $398 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,086,457

Previous 1,539,601 100.47%

Holding current value

$398 Million

Previous $170 Million 127.82%

% of portfolio

0.04%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $135 Million - $198 Million	1,546,856 Added 100.47%	3,086,457 $388 Million
Q1 2025 May 14, 2025	BUY	$107.22 - $153.29 $5.26 Million - $7.52 Million	49,088 Added 3.29%	1,539,601 $170 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $20.6 Million - $25.7 Million	-184,663 Reduced 11.02%	1,490,513 $203 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $14.2 Million - $18.9 Million	-123,672 Reduced 6.88%	1,675,176 $193 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $2.87 Million - $3.14 Million	-21,948 Reduced 1.21%	1,798,848 $248 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $44.8 Million - $49.4 Million	343,847 Added 23.28%	1,820,796 $251 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $31.5 Million - $39.5 Million	297,299 Added 25.2%	1,476,949 $195 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $14.1 Million - $17.6 Million	-150,178 Reduced 11.29%	1,179,650 $133 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $5.76 Million - $6.75 Million	-64,321 Reduced 4.61%	1,329,828 $125 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $2.93 Million - $3.83 Million	-31,141 Reduced 2.18%	1,394,149 $141 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $4.07 Million - $4.84 Million	-38,124 Reduced 2.61%	1,425,290 $170 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $229 Million - $269 Million	-2,492,873 Reduced 63.01%	1,463,414 $155 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $25.2 Million - $33.3 Million	-332,483 Reduced 7.75%	3,956,287 $386 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $5.13 Million - $6.72 Million	-70,875 Reduced 1.63%	4,288,770 $402 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $8.33 Million - $11.1 Million	-104,640 Reduced 2.34%	4,359,645 $371 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $48.7 Million - $55.9 Million	-564,974 Reduced 11.23%	4,464,285 $428 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $66.5 Million - $76.1 Million	-744,100 Reduced 12.89%	5,029,259 $489 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $43.6 Million - $59.5 Million	-498,371 Reduced 7.95%	5,773,359 $561 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $545 Million - $679 Million	6,271,730 New	6,271,730 $601 Million

Others Institutions Holding NBIX

# of Institutions

657

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Neurocrine Biosciences Inc Transaction History